Waystar Considers Sale Amid Stock Decline, Sources Report
Waystar is exploring strategic options, including a sale, following a significant dip in its market value.
Waystar, a prominent healthcare software provider, is evaluating strategic options, including a potential sale, according to seven individuals familiar with the situation. This move comes just two years after the company went public in New York.
Based in Lehi, Utah, and Louisville, Kentucky, Waystar has enlisted the services of investment bank Evercore to advise on the process. The discussions are reportedly in the preliminary stages, with no guarantee that a sale will occur, sources indicated on the condition of anonymity.
Market Valuation and Investor Sentiment
Waystar's market capitalization has dropped to approximately $4.8 billion, following a 24% decrease in its stock price this year. This decline is part of a broader market trend affecting the software sector. An auction could potentially reveal renewed investor interest in software companies.
Initially, Waystar positioned itself as a technology company, focusing on automating healthcare administrative tasks. This strategy aimed to attract higher valuations typically seen in the tech sector. The company's shares surged from $20 to a peak of $45 in 2025. However, concerns about the impact of artificial intelligence on software companies have since pressured the stock, according to a Morgan Stanley report from July.
Company Background and Shareholder Structure
Waystar was formed in 2017 through the merger of Zirmed and Navicure, two healthcare revenue management firms. Major stakeholders include EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital, which took the company public in 2024. EQT remains the largest shareholder with a 13% stake, followed by CPPIB with 10% and BlackRock Institutional Trust Company with 8%, based on data from LSEG.
Neither Waystar nor Evercore provided comments on the ongoing process. Similarly, representatives from EQT, CPPIB, and BlackRock either declined to comment or did not respond to requests.
Industry Context and Future Prospects
The potential sale of Waystar highlights the shifting dynamics within the healthcare software industry, where companies strive for technological advancements to maintain competitive edges. The outcome of Waystar's strategic review could serve as an indicator of investor confidence in the sector.
As Waystar navigates these strategic considerations, the broader software market's performance and technological innovations remain pivotal factors influencing its trajectory. The industry will be closely watching to see if Waystar's exploration of a sale will lead to a significant transaction or if the company will continue its journey as a publicly traded entity.